kidney disease

Swedish rare immunology specialist Hansa Biopharma AB has reported positive topline results from a European post-authorisation efficacy study of Idefirix, strengthening its case to convert the kidney transplant drug’s conditional EU approval into full marketing authorisation.

getty-images-HZfsCshPpiE-unsplash

Perceptic has raised a $12 million (€10.3 million) seed round to advance an AI operating system used by companies including CSL.

getty-images-FB7ex37xAow-unsplash

Adcendo has struck a Keytruda supply agreement with MSD, positioning the Danish biotech to study an antibody-drug conjugate (ADC) with the blockbuster checkpoint inhibitor.

Shopping spree at Eli Lilly? The US pharma giant is acquiring no fewer than three companies, all active in infectious diseases. Among them is Swiss biotech LimmaTech Biologics AG, led by former CureVac CEO Franz-Werner Haas. Yet Lilly’s ambitions extend well beyond classical infectious disease markets, targeting areas ranging from autoimmune disorders and antimicrobial resistance to chronic immune dysfunction and even cancer.

Europe continues to play a pivotal role in the global biologics landscape, combining scientific excellence, regulatory maturity and a strong industrial foundation.

Artificial intelligence is reshaping biotechnology, diagnostics and drug discovery. At the same time, Europe is competing globally for capital, talent and technological leadership. Bio:cap aims to strengthen this ecosystem by connecting investors, startups, researchers and policymakers in a new international investival in Berlin.

Image: Unsplash+

Novo Nordisk has moved a step closer to bringing an oral version of Wegovy to the European obesity market, after the Committee for Medicinal Products for Human Use (CHMP) recommended approval of once-daily oral semaglutide 25 mg for weight management.

Image: Unsplash+

French biotech OSE Immunotherapeutics has reported positive topline Phase II data for its cancer vaccine Tedopi in recurrent ovarian cancer, but the clinical signal is most clearly seen in combination with MSD’s anti-PD-1 antibody Keytruda.

brett-jordan-71oZKsD7Vgg-unsplash

Nanobiotix has temporarily paused trading of its shares in Europe while it prices the €75 million stock offering it launched in the wake of new data on its Johnson & Johnson-partnered lung cancer prospect.

inflex phase 2

A new monoclonal antibody approach could add an infection-directed option to the changing treatment landscape for non-cystic fibrosis bronchiectasis.